Navigation Links
Xpeedior +120 Catheter

ProductsXpeedior +120 Catheter
Company Possis Medical, Inc.
Item Xpeedior +120 Catheter
Features 
  • Proprietary Cross-Stream Technology: Safe removal of adherent vessel wall thrombus
  • .035" guidwire compatible: Works with existing practice tools
  • 6 high velocity saline jets with dual flow windows: Effective 360 thrombus removal
  • Single lumen braided shaft: Enhanced pushability and trackability
  • Low profile tip: Provides atraumatic vessel navigation
  • 15mm dual marker bands: Improved visualization for catheter positioning
  • 120cm length: Additional reach for contralateral approaches
  • Description The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is designed to offer the ultimate in thrombectomy performance. Powerful saline jets create a low pressure zone around the catheter tip causing a vacuum effect. Thrombus is drawn into the catheter, where it is fragmented by the jets, and removed from the body. AngioJet thrombectomy provides rapid restoration of flow in minutes, as opposed to hours with lytic therapy. The Xpeedior+120 catheter has a new 120cm length for additional reach and flexibility for contralateral procedures. The braided shaft offers the strength to get you where you want to go. Dual marker bands help position the catheter and direct the mechanism of action within the vessel. The marker bands are located 15mm apart from center to center. As always, our Xpeedior catheters are 0.035" guidewire compatible to work with your standard practice equipment.
    Info Possis Medical, Inc.
    Customer Service: (800) 810-7677
    Web site: http://www.possis.com

    Related medicine products :

    1. Lumboperitoneal Catheter and Shunt Systems
    2. Bactiseal EVD Catheter
    3. Atlantis SR Pro Coronary Imaging Catheter
    4. Atlantis SR Plus Catheter
    5. Maverick Over-The-Wire 9 mm Catheter
    6. Maverick Over-The-Wire 12 mm Catheter
    7. Maverick Over-The-Wire 15 mm Catheter
    8. Maverick Over-The-Wire 20 mm Catheter
    9. Maverick Over-The-Wire 25 mm Catheter
    10. Maverick Over-The-Wire 30 mm Catheter
    11. Trak Back II Catheter Pull-Back Device
    ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten
    Single-Piece PMMA Intraocular Lenses.
    Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia.
    STABIBAG Hydrophilic Acrylic Lens.
    Medicine Products:
    (Date:11/21/2008).../ -- Heska Corporation,(Nasdaq: HSKA ) today an...,Security Analysts, 12th Annual Biotech and Speci...7 Avenue of the Americas, 2nd Floor in New York, N... a.m. Eastern Time (7:35 a.m.,Mountain Time) and ...ks,following the presentation through a link unde...
    (Date:11/21/2008)...Lennox-Gastaut syndrome , , FRIDAY, Nov....rufinamide) has been approved as a supplementary t...ox-Gastaut syndrome, the U.S. Food and Drug Admini...ased on results of a four-month clinical trial tha...ents who took a placebo, those who took the drug h...
    (Date:11/21/2008)...enter.com, the premier site,for online nursing co...been,updated to improve the interactive experienc...ppincott Williams & Wilkins (LWW), NursingCent...uing education activities and free,access to 11,0...nals.,Lippincott Williams & Wilkins is a part...
    (Date:11/21/2008)...tCall/ -- Today, prescription drugs are the first ...cent of patients suffering chronic conditions. Th...ndition account for 96 percent of all prescription.... A proprietary new pharmacy model developed over...: MHS ) significantly reduces critical gaps in c...
    Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
    ...rma Awareness Month, and to commemorate the occasi...ng Out to Cure Scleroderma walks all share a commo...derma. "These events galvanize our patient commun...le of a little known but often debilitating diseas...
    ... dogs are more active and have less body fat than ...presented today at the 54th American College of Sp.... Dog ownership was associated with higher levels ...n the study, which examined differences in physica...
    ... were charged with corruption Friday for leaking q...d, in a scandal that cast a shadow over the countr... to be charged in connection with the affair, whic...mporary ban on the 17,000 nurses who had passed la...
    ...d a computerised decision analysis programme that ...on as it helps decide on the type of birth that i...veloped by a team of researchers led by Dr Montgom... of Bristol and Dundee. As part of the study, res...
    Other Medicine News:Health News:Dog Owners More Active, Leaner 2Health News:Caesarean Births can Be Reduced by Computer Based Decision Analysis 2
    (Date:11/19/2008)...achieve statistical significance , , ISELIN... Corporation (Nasdaq: PARS ) today announced res...al NanoEmulsion (NE) drug delivery technology form... The multi-center, randomized, double-blinded, p...fficacy of the Company,s 3% Diclofenac Diethanolam...
    (Date:11/19/2008)...9 Biotech scientists increasingly ...esearch to better understand the effects of novel ...orts Genetic Engineering & Biotechnology News...ing out a new compound,s mechanism of action and e...ique, according to the November 15 issue of GEN ....
    (Date:11/19/2008)...nt from Roche- , , MONTVALE, N.J., Nov. 19 ...orp. (Nasdaq: MEMY ) today announced that it has...l of R3487/MEM 3454, its lead alpha-7 nicotinic re... with schizophrenia (CIAS). The Company has rando...g a $5.0 million payment from its partner Roche. ...
    (Date:11/18/2008)...org to learn more, make a donation or send a Chri... Millions will receive C... the American Lung Association. These decorative h...adition dating back to 1907 when the Lung Associat..., "Most Americans alive today have no vivid memo...
    Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 1Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 2Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 3Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 4Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 5Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 6Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 7Human Genome Sciences Reports Positive Data from Long Term Treatment with LymphoStat B 28R 29 in Patients with Active Systemic Lupus Erythematosus 815 8Free Seminar Presents State Funds Back Connection 28TM 29 November 13 in Redding 5940 1Free Seminar Presents State Funds Back Connection 28TM 29 November 13 in Redding 5940 2Free Seminar Presents State Funds Back Connection 28TM 29 November 13 in Redding 5940 3InteKrin Therapeutics Inc Appoints Former Amgen Clinical Development Executive Chief Medical Officer 5935 1InteKrin Therapeutics Inc Appoints Former Amgen Clinical Development Executive Chief Medical Officer 5935 2InteKrin Therapeutics Inc Appoints Former Amgen Clinical Development Executive Chief Medical Officer 5935 3A new mathematical formula for cancer progression 5934 1
    ... SIGA Technologies, Inc.,(NASDAQ: SIGA) announced ... guinea pig trial of its lead Lassa fever virus dr...ety Level 4 conditions at,the U.S. Army Medical Re... by Dr. Kathleen Cashman under the supervision of ... hemorrhagic fever,viruses at USAMRIID for over 12...
    ...l data on leading,drug-eluting stent portfolio, NA...- Boston,Scientific Corporation today announced th... announcements at the annual Paris,Course on Revas...2,to 25 in Barcelona, Spain. , "We will be announc...nd registries, adding to the knowledge base for tr...
    Other Medicine Technology:SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4Boston Scientific Announces Schedule for EuroPcr 2007 2Boston Scientific Announces Schedule for EuroPcr 2007 3Boston Scientific Announces Schedule for EuroPcr 2007 4Boston Scientific Announces Schedule for EuroPcr 2007 5